Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine December 2017, 58 (12) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

GRPR vs. PSMA in prostate cancer: Iagaru looks at the comparative advantages and challenges of prostate-specific membrane antigen− and gastrin-releasing peptide receptor−targeting PET radiopharmaceuticals in prostate cancer.

Page 1883

In vitro evaluation of molecular tumors: Reubi presents the case for employing receptor immunohistochemistry to evaluate potential molecular targets in human tumor tissue sections, with a focus on immunohistochemistry of G-protein–coupled receptors.

Page 1885

18F-FDG PET in parkinsonism: Meyer and colleagues provide an educational overview of current data on the utility of 18F-FDG PET in diagnostic evaluation of parkinsonism and the associated potential for assessment and risk stratification of cognitive impairment.

Page 1888

Theranostic targets in pancreatic cancer: Koller and colleagues report on data-driven prioritization of significantly upregulated proteins in pancreatic ductal adenocarcinoma as potential targets for molecular-based theranostic approaches.

Page 1899

NM training in Europe: Muylle and Maffioli offer perspective on the diversity of training requirements for nuclear medicine physicians in European countries and recent efforts to provide innovative education in emerging modalities and theranostic applications.

Page 1904

18F-FDHT and 18F-FES PET in breast cancer: Venema and colleagues describe concordances between 18F-FDHT and 18F-FES PET imaging and tumor androgen and estrogen receptor expression in patients with metastatic breast cancer.

Page 1906

Dual-timepoint PET/CT in vulvar cancer: Collarino and colleagues assess the value of 18F-FDG PET/CT at 1 and 3 h after tracer injection in prediction of lymph node status in patients with invasive vulvar cancer scheduled for inguinofemoral node dissection.

Page 1913

HNSCC malignancy detection: Rohde and colleagues determine detection rates for distant metastases and synchronous cancers by comparing chest x-ray or CT/head and neck MR imaging with 18F-FDG PET/CT in diagnostic workups of patients with oral, pharyngeal, or laryngeal cancer.

Page 1919

PET and NSCLC outcomes: Steiger and colleagues explore volume-based PET metrics, including metabolic tumor volume, total lesion glycolysis, and background activity–based PET measurements, as prognostic markers for progression-free and overall survival in early-stage non–small cell lung cancer.

Page 1925

Early 18F-FDG PET and CT response: Fledelius and colleagues identify an optimal method for early evaluation with 18F-FDG PET/CT for prediction of later response on CT in patients with erlotinib-treated non–small cell lung cancer.

Page 1931

PSMA PET/CT of synchronous malignancy: Osman and colleagues evaluate the incidence of synchronous primary malignancies in patients undergoing 68Ga-labeled prostate-specific membrane antigen PET/CT for prostate cancer.

Page 1938

PSMA PET/CT and primary PCa: Koerber and colleagues use 68Ga-labeled prostate-specific membrane antigen PET/CT to evaluate SUVs in benign tissue and malignant intraprostatic tumors in patients with newly diagnosed prostate carcinoma and compare these with clinical parameters.

Page 1943

PSMA PET/CT lymph node–positive PCa: Vinsensia and colleagues correlate the dimensions, volume, localization, and SUVmax of nodal metastases identified by 68Ga-PSMA with Gleason score at diagnosis in men with prostate-specific antigen relapse.

Page 1949

68Ga-PSMA-11 PET and patient management: Hope and colleagues estimate the effect of 68Ga-labeled prostate-specific membrane antigen-11 PET on the intended management of patients with biochemically recurrent prostate cancer.

Page 1956

Volumetric 68Ga-PSMA ligand PET: Schmuck and colleagues evaluate whether prostate-specific membrane antigen ligand PET/CT can provide PSMA-derived volumetric parameters for quantification of whole-body tumor burden in patients with metastatic prostate cancer.

Page 1962

PSMA agents and prostate cancer: Hicks and colleagues provide perspective on the successes of 68Ga-labeled prostate-specific membrane antigen agents and preview a paper in this month’s JNM on the prognostic significance of a negative 68Ga-PSMA-11 scan in salvage radiotherapy.

Page 1969

68Ga-PSMA PET–informed treatment: Emmett and colleagues examine the value of prostate-specific membrane antigen–informed salvage radiation treatment in improving outcomes in the context of biochemical failure after radical prostatectomy.

Page 1972

BACE inhibition in transgenic mice: Deleye and colleagues use multitracer PET imaging to investigate the effects of chronic administration of an inhibitor of the β-site amyloid precursor protein–cleaving enzyme 1 on Alzheimer-related pathology in APPPS1-21 mice.

Page 1977

Dual-tracer PET in aging mice: Brendel and colleagues use 18F-FDG and translocator protein small-animal PET to directly examine the link between neuroinflammation and hypermetabolism in aged wild-type mice.

Page 1984

Collagen probe for fibrosis imaging: Désogère and colleagues describe the assessment of several collagen-targeted peptides as PET tracers, including 64Cu-CBP7, a promising probe for identifying and staging pulmonary fibrosis.

Page 1991

18F-FCP PET: Lamichhane and colleagues report on an 18F-labeled carboplatin derivative with the potential for personalized PET imaging of drug uptake and retention, including intratumoral distribution.

Page 1997

18F-FTC-146 dosimetry: Hjørnevik and colleagues assess the safety, biodistribution, and radiation dosimetry in humans of this highly selective σ-1 receptor PET agent with potential for application in a variety of neuroinflammatory diseases.

Page 2004

Adverse reactions to radiopharmaceuticals: Kennedy-Dixon and colleagues look at reports submitted to the British Nuclear Medicine Society’s online database in a 10-year period to determine the prevalence of adverse reactions associated with radiopharmaceuticals.

Page 2010

MBF with SPECT or PET: Wells and colleagues compare myocardial blood flow and myocardial flow reserve measurements acquired with 99mTc-tetrofosmin SPECT and with 82Rb or 13N-ammonia PET.

Page 2013

Scatter correction in 15O-gas PET: Magota and colleagues examine the validity of a newly developed scatter-correction method for accurate quantitative assessment in 15O-gas brain PET that combines single-scatter simulation with a scaling factor calculated by Monte Carlo simulation.

Page 2020

AUC for 18F-FDG PET/CT: Jadvar and colleagues from U.S. and European molecular imaging and oncology associations present evidence-based appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response of malignant disease.

Page 2026

  • © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (12)
Journal of Nuclear Medicine
Vol. 58, Issue 12
December 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Dec 2017, 58 (12) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Dec 2017, 58 (12) 8A;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease
  • Time Courses of Cortical Glucose Metabolism and Microglial Activity Across the Life Span of Wild-Type Mice: A PET Study
  • Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies
  • Data-Driven Prioritization and Review of Targets for Molecular-Based Theranostic Approaches in Pancreatic Cancer
  • Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer
  • Head-to-Head Comparison of Chest X-Ray/Head and Neck MRI, Chest CT/Head and Neck MRI, and 18F-FDG PET/CT for Detection of Distant Metastases and Synchronous Cancer in Oral, Pharyngeal, and Laryngeal Cancer
  • Analysis of Prognostic Values of Various PET Metrics in Preoperative 18F-FDG PET for Early-Stage Bronchial Carcinoma for Progression-Free and Overall Survival: Significantly Increased Glycolysis Is a Predictive Factor
  • Detection of Synchronous Primary Malignancies with 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients
  • 18F-Labeled Carboplatin Derivative for PET Imaging of Platinum Drug Distribution
  • 68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters
  • Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease
  • Treatment Outcomes from 68Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET
  • 68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer
  • 18F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non–Small Cell Lung Cancer Patients: A Comparison of Assessment Methods
  • 18F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment
  • In Vitro Evaluation of Molecular Tumor Targets in Nuclear Medicine: Immunohistochemistry Is One Option, but Under Which Conditions?
  • Will GRPR Compete with PSMA as a Target in Prostate Cancer?
  • Evaluation of Radiopharmaceutical Adverse Reaction Reports to the British Nuclear Medicine Society from 2007 to 2016
  • Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment
  • Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis
  • Evaluation of Dual-Timepoint 18F-FDG PET/CT Imaging for Lymph Node Staging in Vulvar Cancer
  • Optimization of SPECT Measurement of Myocardial Blood Flow with Corrections for Attenuation, Motion, and Blood Binding Compared with PET
  • Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer
  • Scatter Correction with Combined Single-Scatter Simulation and Monte Carlo Simulation Scaling Improved the Visual Artifacts and Quantification in 3-Dimensional Brain PET/CT Imaging with 15O-Gas Inhalation
  • Nuclear Medicine Training in Europe: “All for One, One for All”
  • Biodistribution and Radiation Dosimetry of 18F-FTC-146 in Humans
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire